San Francisco, CA—According to results from a retrospective analysis of nearly 12,000 patients with cancer, increased social support may function as an analgesic and help to mitigate pain.
Orlando, FL—Chimeric antigen receptor (CAR) T-cell therapy is now approved as third-line treatment for patients with B-cell lymphomas and leukemias. For some patients, CAR T-cell therapy is a miracle therapy, extending survival and, in some cases, as a bridge to a potentially curative transplant. But at an estimated cost of $375,000 to $475,000 per person, many people have questioned the value of this treatment, and whether it can be delivered effectively to patients not enrolled in clinical trials.
To sign up for our newsletter or print publications, please enter your contact information below.
